Glaucoma is a group of diseases that exhibit a characteristic optic neuropathy which, untreated, initially causes loss of peripheral and ultimately central vision. It is a leading cause of blindness worldwide and is estimated to affect over three million people in the United States. Although vision loss due to glaucoma is irreversible, blindness can typically be prevented when it is detected and treated in its earlier stages. A number of different medication classes are currently in use to treat glaucoma, including prostaglandin analogues, B-adrenergic antagonists, adrenergic agonists, carbonic anhydrase inhibitors, parasympathomimetics, and hyperosmotic agents. In general, these medications reduce IOP either by reducing aqueous humor secretion from the ciliary body or by increasing aqueous outflow from the eye.
Hyperosmotic agents in glaucoma treatment Elevated intraocular pressure Glaucoma medical treatment Prostaglandin analogues in glaucoma β-antagonists in glaucoma treatment Carbonic anhydrase inhibitors in glaucoma Parasympathomimetic agents in glaucoma Hyperosmotics in glaucoma treatment
This is a preview of subscription content, log in to check access.
Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Group. Ophthalmology. 1996;103(11):1916–24.CrossRefGoogle Scholar
Lee AG, Anderson R, Kardon RH, Wall M. Presumed “sulfa allergy” in patients with intracranial hypertension treated with acetazolamide or furosemide cross-reactivity, myth or reality? Am J Ophthalmol. 2004;138(1):114–8.CrossRefGoogle Scholar
Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138(3):389–95.CrossRefGoogle Scholar